Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Paul Edward Sax, M.D.

TitleProfessor of Medicine
InstitutionBrigham and Women's Hospital
DepartmentMedicine
AddressBrigham and Women's Hospital
Infectious Diseases
75 Francis St
Boston MA 02115
Phone617/732-7460
Fax617/732-6829

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. McComsey GA, Kitch D, Sax PE, Tierney C, Jahed NC, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N, Daar ES. Associations of Inflammatory Markers With AIDS and Non-AIDS Clinical Events After Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202. J Acquir Immune Defic Syndr. 2014 Feb 1; 65(2):167-74.
    View in: PubMed
  2. Grant PM, Tierney C, Budhathoki C, Daar ES, Sax PE, Collier AC, Fischl MA, Zolopa AR, Balamane M, Katzenstein D. Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202. HIV Clin Trials. 2013 Nov-Dec; 14(6):284-91.
    View in: PubMed
  3. Hyle EP, Sax PE, Walensky RP. Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy. JAMA Intern Med. 2013 Oct 14; 173(18):1746-8.
    View in: PubMed
  4. Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Tebas P, Melbourne K, Ha B, Jahed NC, McComsey GA. Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS. 2013 Aug 24; 27(13):2069-79.
    View in: PubMed
  5. Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, Wohl D, Gallant JE, Liu HC, Plummer A, White KL, Cheng AK, Rhee MS, Szwarcberg J. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013 May 1; 63(1):96-100.
    View in: PubMed
  6. Wood BR, Komarow L, Zolopa AR, Finkelman MA, Powderly WG, Sax PE. Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms. AIDS. 2013 Mar 27; 27(6):967-72.
    View in: PubMed
  7. Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, Paltiel AD, Schackman BR. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013 Jan 15; 158(2):84-92.
    View in: PubMed
  8. Sax PE. Editorial Commentary: Can We Break the Habit of Routine CD4 Monitoring in HIV Care? Clin Infect Dis. 2013 May; 56(9):1344-6.
    View in: PubMed
  9. Schackman BR, Haas DW, Becker JE, Berkowitz BK, Sax PE, Daar ES, Ribaudo HJ, Freedberg KA. Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. Antivir Ther. 2013; 18(3):399-408.
    View in: PubMed
  10. McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE, Gerschenson M. Changes in Fat Mitochondrial DNA and Function in Subjects Randomized to Abacavir-Lamivudine or Tenofovir DF-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: AIDS Clinical Trials Group Study A5224s, Substudy of A5202. J Infect Dis. 2013 Feb; 207(4):604-11.
    View in: PubMed
  11. Ribaudo HJ, Daar ES, Tierney C, Morse GD, Mollan K, Sax PE, Fischl MA, Collier AC, Haas DW. Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-Boosted Atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis. 2013 Feb; 207(3):420-5.
    View in: PubMed
  12. Mollan K, Daar ES, Sax PE, Balamane M, Collier AC, Fischl MA, Lalama CM, Bosch RJ, Tierney C, Katzenstein D. HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. J Infect Dis. 2012 Dec 15; 206(12):1920-30.
    View in: PubMed
  13. Zolopa A, Gallant J, Cohen C, Sax P, Dejesus E, Mills A, Wohl D, Liu H, Rhee M, Szwarcberg J. Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-naïve HIV-1-infected patients. J Int AIDS Soc. 2012; 15(6):18219.
    View in: PubMed
  14. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N, Sax PE. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS. 2012 Jul 17; 26(11):1371-85.
    View in: PubMed
  15. Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012 Jun 30; 379(9835):2439-48.
    View in: PubMed
  16. Gandhi RT, Sax PE, Grinspoon SK. Metabolic and cardiovascular complications in HIV-infected patients: new challenges for a new age. J Infect Dis. 2012 Jun; 205 Suppl 3:S353-4.
    View in: PubMed
  17. Szent-Gyorgyi LE, Desai S, Kim D, Sax PE, Greenberg JO. Removing legal barriers to high-quality care for HIV-infected patients. N Engl J Med. 2012 Apr 5; 366(14):1268-70.
    View in: PubMed
  18. Aberg JA, Tebas P, Overton ET, Gupta SK, Sax PE, Landay A, Falcon R, Ryan R, De La Rosa G. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012 Oct; 28(10):1184-95.
    View in: PubMed
  19. Lockman S, Sax P. Treatment-for-prevention: clinical considerations. Curr Opin HIV AIDS. 2012 Mar; 7(2):131-9.
    View in: PubMed
  20. Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One. 2012; 7(2):e31591.
    View in: PubMed
  21. Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR. Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development. HIV Clin Trials. 2012 Jan-Feb; 13(1):1-10.
    View in: PubMed
  22. Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011 Oct 15; 204(8):1191-201.
    View in: PubMed
  23. Sax PE. Antiretroviral therapy: now "it just works". Clin Infect Dis. 2011 Sep; 53(6):605-8.
    View in: PubMed
  24. McComsey GA, Kitch D, Sax PE, Tebas P, Tierney C, Jahed NC, Myers L, Melbourne K, Ha B, Daar ES. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis. 2011 Jul 15; 53(2):185-96.
    View in: PubMed
  25. Sax PE, Komarow L, Finkelman MA, Grant PM, Andersen J, Scully E, Powderly WG, Zolopa AR. Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis. 2011 Jul 15; 53(2):197-202.
    View in: PubMed
  26. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011 Jun 15; 203(12):1791-801.
    View in: PubMed
  27. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Pappa KA, Woodward WC, Patterson K, Bolivar H, Benson CA, Collier AC. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011 Apr 5; 154(7):445-56.
    View in: PubMed
  28. April MD, Chiosi JJ, Paltiel AD, Sax PE, Walensky RP. Projected survival gains from revising state laws requiring written opt-in consent for HIV testing. J Gen Intern Med. 2011 Jun; 26(6):661-7.
    View in: PubMed
  29. Hsu HE, Rydzak CE, Cotich KL, Wang B, Sax PE, Losina E, Freedberg KA, Goldie SJ, Lu Z, Walensky RP. Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med. 2011 Feb; 12(2):97-108.
    View in: PubMed
  30. Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr. 2010 Dec 15; 55(5):615-9.
    View in: PubMed
  31. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G, Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC, Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL, Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, Mcleod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O'Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC, Olender SA, Ostrowski M, Owen WF, Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM, Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Telenti A, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, van't Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao M. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010 Dec 10; 330(6010):1551-7.
    View in: PubMed
  32. Rydzak CE, Cotich KL, Sax PE, Hsu HE, Wang B, Losina E, Freedberg KA, Weinstein MC, Goldie SJ. Assessing the performance of a computer-based policy model of HIV and AIDS. PLoS One. 2010; 5(9).
    View in: PubMed
  33. Sax PE, Sloan CE, Schackman BR, Grant PM, Rong J, Zolopa AR, Powderly W, Losina E, Freedberg KA. Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. HIV Clin Trials. 2010 Sep-Oct; 11(5):248-59.
    View in: PubMed
  34. Bassett IV, Sax PE. Untreated HIV: harmful even at high CD4 cell counts. Lancet. 2010 Jul 31; 376(9738):306-8.
    View in: PubMed
  35. Linas BP, Wang B, Smurzynski M, Losina E, Bosch RJ, Schackman BR, Rong J, Sax PE, Walensky RP, Schouten J, Freedberg KA. The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat. 2011 Jul; 18(7):506-12.
    View in: PubMed
  36. Sax PE. A nay vote for early ART in patients with cryptococcal meningitis. J Watch AIDS Clin Care. 2010 Jun; 22(6):50-1.
    View in: PubMed
  37. Li JZ, Sax PE. AZT or tenofovir for patients with the K65R mutation? J Watch AIDS Clin Care. 2010 Jun; 22(6):51-2.
    View in: PubMed
  38. Rosenberg ES, Graham BS, Chan ES, Bosch RJ, Stocker V, Maenza J, Markowitz M, Little S, Sax PE, Collier AC, Nabel G, Saindon S, Flynn T, Kuritzkes D, Barouch DH. Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One. 2010; 5(5):e10555.
    View in: PubMed
  39. Sax PE. Report from the 17th Conference on Retroviruses and Opportunistic Infections. Non-AIDS-related adverse effects of HIV and its treatment. J Watch AIDS Clin Care. 2010 Apr; 22(4):31.
    View in: PubMed
  40. Sax PE. Report from the 17th Conference on Retroviruses and Opportunistic Infections. Randomized studies of once-daily darunavir and tenofovir/FTC + nevirapine. J Watch AIDS Clin Care. 2010 Apr; 22(4):33-4.
    View in: PubMed
  41. Sax PE. Report from the 17th Conference on Retroviruses and Opportunistic Infections. Transmitted HIV-drug resistance in the U.S. J Watch AIDS Clin Care. 2010 Apr; 22(4):34.
    View in: PubMed
  42. Sax PE. Maraviroc for treatment-naive patients with HIV-1 infection: is the glass half empty or half full? J Infect Dis. 2010 Mar 15; 201(6):797-9.
    View in: PubMed
  43. Parienti JJ. A controlled trial of initial antiviral regimens for HIV-1 infection. N Engl J Med. 2010 Mar 4; 362(9):854; author reply 855.
    View in: PubMed
  44. Robbins GK, Johnson KL, Chang Y, Jackson KE, Sax PE, Meigs JB, Freedberg KA. Predicting virologic failure in an HIV clinic. Clin Infect Dis. 2010 Mar 1; 50(5):779-86.
    View in: PubMed
  45. Sax PE. Assessing risk for cardiovascular disease in patients with human immunodeficiency virus: Why it matters. Circulation. 2010 Feb 9; 121(5):620-2.
    View in: PubMed
  46. Sax PE. Early ART in the setting of acute OIs. Major trials support this approach, but the strategy is not without risk. J Watch AIDS Clin Care. 2010 Jan; 22(1):6.
    View in: PubMed
  47. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009 Dec 3; 361(23):2230-40.
    View in: PubMed
  48. Sax PE. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abacavir and CVD--again. J Watch AIDS Clin Care. 2009 Oct; 21(10):81.
    View in: PubMed
  49. Sax PE. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. J Watch AIDS Clin Care. 2009 Oct; 21(10):79.
    View in: PubMed
  50. Sax PE. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Nevirapine vs. boosted atazanavir--the ARTEN Study. J Watch AIDS Clin Care. 2009 Oct; 21(10):80.
    View in: PubMed
  51. Johnson JA, Sax PE. Antiretroviral therapy for treatment-naïve patients: a review of recent literature and the updated guidelines. Curr Infect Dis Rep. 2009 Jul; 11(4):311-8.
    View in: PubMed
  52. Li JZ, Sax PE. HSV-1 encephalitis complicated by cerebral hemorrhage in an HIV-positive person. AIDS Read. 2009 Apr; 19(4):153-5.
    View in: PubMed
  53. Sax PE. Report from the 16th Conference on Retroviruses and Opportunistic Infections. Concomitant HIV/TB treatment improves survival. J Watch AIDS Clin Care. 2009 Apr; 21(4):31.
    View in: PubMed
  54. Boyle BA, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle GJ, Sax PE. Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use. AIDS Read. 2009 Apr; 19(4):158-60.
    View in: PubMed
  55. Sax PE, Baden LR. When to start antiretroviral therapy--ready when you are? N Engl J Med. 2009 Apr 30; 360(18):1897-9.
    View in: PubMed
  56. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR, Sloan CE, Sax PE, Walensky RP. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009 Mar 15; 48(6):806-15.
    View in: PubMed
  57. Boyle BA, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle GJ, Sax P. Antiretroviral therapy update from the 48th ICAAC/46th IDSA annual meeting. AIDS Read. 2009 Jan; 19(1):22-31.
    View in: PubMed
  58. Sax PE. Top stories of 2008. Newer drugs strikingly effective when given together. AIDS Clin Care. 2009 Jan; 21(1):3.
    View in: PubMed
  59. Bloom A, Jackson K, Kiviat A, Zheng H, Sax P, Gandhi R. Repeat hepatitis B vaccination may lead to seroprotection in HIV-infected patients who do not respond to an initial series. J Acquir Immune Defic Syndr. 2009 Jan 1; 50(1):110-3.
    View in: PubMed
  60. Ciaranello AL, Walensky RP, Sax PE, Chang Y, Freedberg KA, Weissman JS. Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents. HIV Clin Trials. 2009 Jan-Feb; 10(1):13-24.
    View in: PubMed
  61. Sax PE. Report from the 2008 joint ICAAC/IDSA meeting. Bevirimat: predictors of response. AIDS Clin Care. 2008 Dec; 20(12):104.
    View in: PubMed
  62. Sax PE. Report from the 2008 joint ICAAC/IDSA meeting. Darunavir and atazanavir: 96-week data from ARTEMIS and CASTLE. AIDS Clin Care. 2008 Dec; 20(12):98.
    View in: PubMed
  63. Sax PE. A single case of cure? AIDS Clin Care. 2008 Dec; 20(12):103.
    View in: PubMed
  64. Sax PE. Report from the 2008 joint ICAAC/IDSA meeting. Maraviroc vs. efavirenz: a reanalysis of MERIT. AIDS Clin Care. 2008 Dec; 20(12):98, 104.
    View in: PubMed
  65. Sax PE. Report from the 2008 joint ICAAC/IDSA meeting. Early ART and overall survival. AIDS Clin Care. 2008 Dec; 20(12):97.
    View in: PubMed
  66. Sax PE. Report from the 2008 joint ICAAC/IDSA meeting. More data on abacavir/3TC. AIDS Clin Care. 2008 Dec; 20(12):104.
    View in: PubMed
  67. Sax PE. Darunavir now approved for use in treatment-naive patients. AIDS Clin Care. 2008 Dec; 20(12):102.
    View in: PubMed
  68. Sax PE. Report from the 2008 joint ICAAC/IDSA meeting. Raltegravir vs. efavirenz in treatment-naive patients. AIDS Clin Care. 2008 Dec; 20(12):97.
    View in: PubMed
  69. Boyle B, Cohen C, DeJesus E, Elion R, Frank I, Moyle G, Sax P. Antiretroviral treatment update from the 17th International AIDS Conference. AIDS Read. 2008 Nov; 18(11):570-9.
    View in: PubMed
  70. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008 Oct 1; 22(15):2025-33.
    View in: PubMed
  71. Rawizza HE, Sax PE. Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases. AIDS Read. 2008 Sep; 18(9):466-72, 478-9.
    View in: PubMed
  72. Sax PE. Preventing and treating HIV-related OIs--updated guidelines. AIDS Clin Care. 2008 Sep; 20(9):75.
    View in: PubMed
  73. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, Schouten JT, Smieja M. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008 Jul 8; 118(2):e29-35.
    View in: PubMed
  74. Pisculli ML, Sax PE. Use of a serum beta-glucan assay for diagnosis of HIV-related Pneumocystis jiroveci pneumonia in patients with negative microscopic examination results. Clin Infect Dis. 2008 Jun 15; 46(12):1928-30.
    View in: PubMed
  75. Huang HY, Daar ES, Sax PE, Young B, Cook P, Benson P, Cohen C, Scribner A, Hu H. The prevalence of transmitted antiretroviral drug resistance in treatment-naïve patients and factors influencing first-line treatment regimen selection. HIV Med. 2008 May; 9(5):285-93.
    View in: PubMed
  76. Boyle BA, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle GJ, Sax P. Update on antiretroviral therapy: the 15th CROI. AIDS Read. 2008 May; 18(5):273-8, C3.
    View in: PubMed
  77. Sax PE. Report from the 15th Retrovirus Conference. Etravirine resistance: baseline prevalence and proposed criteria for "vircotype". AIDS Clin Care. 2008 Apr; 20(4):30.
    View in: PubMed
  78. Sax PE. Revised package insert for atazanavir. AIDS Clin Care. 2008 Mar; 20(3):23.
    View in: PubMed
  79. Sax PE. FDA approval: etravirine. AIDS Clin Care. 2008 Mar; 20(3):17-8.
    View in: PubMed
  80. Sax PE. Top stories of 2007. AIDS Clin Care. 2008 Jan; 20(1):1-3.
    View in: PubMed
  81. Sax PE. Lower dose of ritonavir approved for use with fosamprenavir. AIDS Clin Care. 2007 Dec; 19(12):106.
    View in: PubMed
  82. Sax PE. Report from the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. AIDS Clin Care. 2007 Nov; 19(11):99-100.
    View in: PubMed
  83. Yazdanpanah Y, Vray M, Meynard J, Losina E, Weinstein MC, Morand-Joubert L, Goldie SJ, Hsu HE, Walensky RP, Dalban C, Sax PE, Girard PM, Freedberg KA. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med. 2007 Oct; 8(7):439-50.
    View in: PubMed
  84. Schackman BR, Scott CA, Sax PE, Losina E, Wilkin TJ, McKinnon JE, Swindells S, Weinstein MC, Freedberg KA. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis. 2007 Oct 15; 45(8):1062-70.
    View in: PubMed
  85. Sax PE. FDA approval: maraviroc. AIDS Clin Care. 2007 Sep; 19(9):75.
    View in: PubMed
  86. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007 Jun; 56(6):1754-64.
    View in: PubMed
  87. Boyle BA, Elion R, Cohen CJ, Moyle GJ, Sax P, Frank I. Advances in HIV therapeutics: the 14th CROI. AIDS Read. 2007 May; 17(5):268-70, 272-4, 283-6.
    View in: PubMed
  88. Sax PE. Report from the 14th Retrovirus Conference. Treatment options for antiretroviral-naive patients. AIDS Clin Care. 2007 May; 19(5):38-9.
    View in: PubMed
  89. Sax PE, Gallant JE, Klotman PE. Renal safety of tenofovir disoproxil fumarate. AIDS Read. 2007 Feb; 17(2):90-2, 99-104, C3.
    View in: PubMed
  90. Sax PE. Meeting report. Report from ICAAC. AIDS Clin Care. 2006 Dec; 18(12):111-2.
    View in: PubMed
  91. Sax PE. Updated DHHS treatment guidelines. AIDS Clin Care. 2006 Dec; 18(12):105.
    View in: PubMed
  92. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR, Moore RD, Freedberg KA. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006 Nov; 44(11):990-7.
    View in: PubMed
  93. Boyle BA, Cohen CJ, Moyle GJ, Elion R, Sax PE, Frank I. XVI International AIDS Conference: Part 2. AIDS Read. 2006 Nov; 16(11):581-4, 591-2.
    View in: PubMed
  94. Sax PE. Report from the XVI International AIDS Conference. Preexposure prophylaxis studies move forward. AIDS Clin Care. 2006 Nov; 18(11):101-2.
    View in: PubMed
  95. Sax P. Report from the XVI International AIDS Conference. "KLEAN" results with fosamprenavir/ritonavir. AIDS Clin Care. 2006 Nov; 18(11):98.
    View in: PubMed
  96. Boyle BA, Cohen CJ, Moyle GJ, Elion R, Sax PE, Frank I. XVI International AIDS Conference: Part 1. AIDS Read. 2006 Oct; 16(10):517-21.
    View in: PubMed
  97. Sax PE. Evaluation and management of early virological failure. Curr Opin HIV AIDS. 2006 Sep; 1(5):409-16.
    View in: PubMed
  98. Sax PE. One pill, once daily: now an option for HIV patients. AIDS Clin Care. 2006 Sep; 18(9):77.
    View in: PubMed
  99. Sax PE. FDA approval: darunavir. AIDS Clin Care. 2006 Aug; 18(8):71.
    View in: PubMed
  100. McGovern BH, Ditelberg JS, Taylor LE, Gandhi RT, Christopoulos KA, Chapman S, Schwartzapfel B, Rindler E, Fiorino AM, Zaman MT, Sax PE, Graeme-Cook F, Hibberd PL. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis. 2006 Aug 1; 43(3):365-72.
    View in: PubMed
  101. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006 Jul 1; 194(1):11-9.
    View in: PubMed
  102. Sax PE. Therapeutic options for treatment experienced patients: a focus on resistance testing and optimizing background therapy. AIDS Read. 2006 May; 16(5):265-75, 277-8.
    View in: PubMed
  103. Sax PE. Report from the 13th retrovirus conference. Vicriviroc less effective than efavirenz in treatment-naive patients. AIDS Clin Care. 2006 Apr; 18(4):34-5.
    View in: PubMed
  104. Sax PE. Report from the 13th retrovirus conference. Should we be starting treatment earlier? AIDS Clin Care. 2006 Apr; 18(4):36.
    View in: PubMed
  105. Sax PE. Report from the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. AIDS Clin Care. 2006 Mar; 18(3):25-6.
    View in: PubMed
  106. Appelbaum JS, Elion R, Henry K, Newman MD, Saag MS, Sax PE. Roundtable. Who should be providing HIV care? AIDS Clin Care. 2006 Mar; 18(3):21-4.
    View in: PubMed
  107. Kassutto S, Maghsoudi K, Johnston MN, Robbins GK, Burgett NC, Sax PE, Cohen D, Pae E, Davis B, Zachary K, Basgoz N, D'agata EM, DeGruttola V, Walker BD, Rosenberg ES. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis. 2006 Apr 1; 42(7):1024-31.
    View in: PubMed
  108. Sax PE. Strategies for management and treatment of dyslipidemia in HIV/AIDS. AIDS Care. 2006 Feb; 18(2):149-57.
    View in: PubMed
  109. Sax PE, Yawetz S, Workowski KA. Antiretroviral rounds. The ABCs of LGV. AIDS Clin Care. 2005 Nov; 17(11):106-7.
    View in: PubMed
  110. Sax PE. Meeting notes from the 3rd IAS Conference. Advances in the treatment of hepatitis/HIV coinfection. AIDS Clin Care. 2005 Oct; 17(10):97-8.
    View in: PubMed
  111. Garlin AB, Sax PE. Retroviral rebound syndrome with fatal outcome after discontinuation of antiretroviral therapy. Clin Infect Dis. 2005 Nov 1; 41(9):e83-5.
    View in: PubMed
  112. Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, Sadownik SN, Freedberg KA. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005 Nov 1; 41(9):1316-23.
    View in: PubMed
  113. Sax PE, Gathe JC. Beyond efficacy: the impact of combination antiretroviral therapy on quality of life. AIDS Patient Care STDS. 2005 Sep; 19(9):563-76.
    View in: PubMed
  114. Sax PE. FDA approval: tipranavir. AIDS Clin Care. 2005 Aug; 17(8):78.
    View in: PubMed
  115. Sax PE, Losina E, Weinstein MC, Paltiel AD, Goldie SJ, Muccio TM, Kimmel AD, Zhang H, Freedberg KA, Walensky RP. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2005 May 1; 39(1):69-77.
    View in: PubMed
  116. Sax PE. Report from the 12th Retrovirus Conference. New drugs. AIDS Clin Care. 2005 Apr; 17(4):37.
    View in: PubMed
  117. Sax PE. Report from the 12th Retrovirus Conference. Resistance. AIDS Clin Care. 2005 Apr; 17(4):36-7.
    View in: PubMed
  118. Gandhi RT, Wurcel A, Lee H, McGovern B, Shopis J, Geary M, Sivamurthy R, Sax PE, Ukomadu C. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis. 2005 May 1; 191(9):1435-41.
    View in: PubMed
  119. Walensky RP, Weinstein MC, Kimmel AD, Seage GR, Losina E, Sax PE, Zhang H, Smith HE, Freedberg KA, Paltiel AD. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med. 2005 Mar; 118(3):292-300.
    View in: PubMed
  120. Fichtenbaum CJ, Hadigan CM, Kotler DP, Pierone G, Sax PE, Steinhart CR, Tebas P. Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care. IAPAC Mon. 2005 Feb; 11(2):38-46.
    View in: PubMed
  121. Sax PE. Revised guidelines for the treatment of OIs. AIDS Clin Care. 2005 Feb; 17(2):13-4.
    View in: PubMed
  122. Sax PE. Meeting notes from ICAAC. Choosing the right HCV-coinfected patients to treat. AIDS Clin Care. 2005 Jan; 17(1):7-8.
    View in: PubMed
  123. Sax PE. Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid. AIDS Clin Care. 2005 Jan; 17(1):6-7.
    View in: PubMed
  124. Sax PE. Meeting notes from ICAAC. D-D4FC (Reverset): further data on treatment-experienced patients. AIDS Clin Care. 2005 Jan; 17(1):8.
    View in: PubMed
  125. Sax PE. Meeting notes from ICAAC. NRTI-only regimens: making a comeback? AIDS Clin Care. 2005 Jan; 17(1):8-9.
    View in: PubMed
  126. Sax PE. Top stories of 2004. Back to the future: lopinavir/ritonavir as "monotherapy". AIDS Clin Care. 2005 Jan; 17(1):4.
    View in: PubMed
  127. Sax PE, Kumar P. Tolerability and safety of HIV protease inhibitors in adults. J Acquir Immune Defic Syndr. 2004 Sep 1; 37(1):1111-24.
    View in: PubMed
  128. Sax PE. Meeting report from the XV International AIDS Conference. Structured treatment interruption and other novel treatment strategies. AIDS Clin Care. 2004 Sep; 16(9):72-3.
    View in: PubMed
  129. Sax PE. Meeting report from the XV International AIDS Conference. New drugs. AIDS Clin Care. 2004 Sep; 16(9):71-2.
    View in: PubMed
  130. McComsey GA, Huang JS, Woolley IJ, Young B, Sax PE, Gerber M, Swindells S, Bonilla H, Gopalakrishnan G. Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management. J Int Assoc Physicians AIDS Care (Chic). 2004 Jul-Sep; 3(3):86-91.
    View in: PubMed
  131. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med. 2004 May 18; 140(10):786-94.
    View in: PubMed
  132. Losina E, Islam R, Pollock AC, Sax PE, Freedberg KA, Walensky RP. Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview. Clin Infect Dis. 2004 Jun 1; 38(11):1613-22.
    View in: PubMed
  133. Ivers LC, Kim AY, Sax PE. Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma. Clin Infect Dis. 2004 Jun 1; 38(11):1629-32.
    View in: PubMed
  134. Sax PE. Report from the 11th conference on retroviruses and opportunistic infections. New drugs. AIDS Clin Care. 2004 Apr; 16(4):29.
    View in: PubMed
  135. Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR, Kimmel AD, Walensky RP, Sax PE, Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003 Dec 1; 115(8):632-41.
    View in: PubMed
  136. Gandhi RT, Wurcel A, McGovern B, Lee H, Shopis J, Corcoran CP, Toner S, Giachetti C, Dockter J, Sax PE, Ukomadu C. Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen. J Acquir Immune Defic Syndr. 2003 Dec 1; 34(4):439-41.
    View in: PubMed
  137. Sax PE. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). New NNRTI resistance mutations. AIDS Clin Care. 2003 Nov; 15(11):96.
    View in: PubMed
  138. Sax PE. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abacavir as initial therapy and as a once-daily drug. AIDS Clin Care. 2003 Nov; 15(11):93-4.
    View in: PubMed
  139. Sax PE. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. New drugs. AIDS Clin Care. 2003 Sep; 15(9):80-1.
    View in: PubMed
  140. Sax PE. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients. AIDS Clin Care. 2003 Sep; 15(9):78.
    View in: PubMed
  141. Sax PE. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Resistance rates in treatment-naive patients. AIDS Clin Care. 2003 Sep; 15(9):80.
    View in: PubMed
  142. Gandhi RT, Wurcel A, Lee H, McGovern B, Boczanowski M, Gerwin R, Corcoran CP, Szczepiorkowski Z, Toner S, Cohen DE, Sax PE, Ukomadu C. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis. 2003 Jun 15; 36(12):1602-5.
    View in: PubMed
  143. Tremblay CL, Hicks JL, Sutton L, Giguel F, Flynn T, Johnston M, Sax PE, Walker BD, Hirsch MS, Rosenberg ES, D'Aquila RT. Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection. AIDS. 2003 May 2; 17(7):1086-9.
    View in: PubMed
  144. Hicks C, Currier J, Sax P, Sherer R, Wanke C. Current management challenges in HIV: tolerability of antiretrovirals and metabolic complications. AIDS Patient Care STDS. 2003 May; 17(5):221-33.
    View in: PubMed
  145. Sax PE. Report from the Tenth Retrovirus Conference. New drugs. AIDS Clin Care. 2003 Apr; 15(4):32-3.
    View in: PubMed
  146. Sax PE. Report from the Tenth Retrovirus Conference. Comparing efavirenz and nevirapine: the 2NN study. AIDS Clin Care. 2003 Apr; 15(4):32.
    View in: PubMed
  147. Hadigan C, Meigs JB, Wilson PW, D'Agostino RB, Davis B, Basgoz N, Sax PE, Grinspoon S. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis. 2003 Apr 1; 36(7):909-16.
    View in: PubMed
  148. O'Rourke M, Branson B, del Rio C, Larrabee S, Sax PE. Rapid fingerstick testing: a new era in HIV diagnostics. AIDS Clin Care. 2003 Mar; 15(3):19-23, 30.
    View in: PubMed
  149. Kassutto S, Sax PE. HIV and syphilis coinfection: trends and interactions. AIDS Clin Care. 2003 Feb; 15(2):9-15.
    View in: PubMed
  150. Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, Goldie SJ. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002 Nov 25; 162(21):2478-86.
    View in: PubMed
  151. Walensky RP, Goldie SJ, Sax PE, Weinstein MC, Paltiel AD, Kimmel AD, Seage GR, Losina E, Zhang H, Islam R, Freedberg KA. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr. 2002 Sep 1; 31(1):27-37.
    View in: PubMed
  152. Abdool Karim SS, Currier J, del Rio C, Feinberg J, Friedland GH, Sax PE, Zuger A. Report on the XIV International AIDS Conference. AIDS Clin Care. 2002 Sep; 14(9):77-85.
    View in: PubMed
  153. Colson AE, Keller MJ, Sax PE, Pettus PT, Platt R, Choo PW. Male sexual dysfunction associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002 May 1; 30(1):27-32.
    View in: PubMed
  154. Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour AJ, Sun E. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002 Mar 1; 185(5):599-607.
    View in: PubMed
  155. Vidrih JA, Walensky RP, Sax PE, Freedberg KA. Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection. Am J Med. 2001 Aug 15; 111(3):192-4.
    View in: PubMed
  156. Sax P. Changes in drug economy in Israel's health maintenance organizations in the wake of the National Health Insurance Law. Isr Med Assoc J. 2001 Aug; 3(8):605-9.
    View in: PubMed
  157. Sax PE. Opportunistic infections in HIV disease: down but not out. Infect Dis Clin North Am. 2001 Jun; 15(2):433-55.
    View in: PubMed
  158. Bender MA, Sax PE. Discontinuing prophylaxis against Pneumocystis carinii pneumonia. N Engl J Med. 2001 May 24; 344(21):1639; author reply 1640-1.
    View in: PubMed
  159. Landovitz RJ, Sax PE. NRTI-associated mitochondrial toxicity. AIDS Clin Care. 2001 May; 13(5):43-5, 48-9, 52.
    View in: PubMed
  160. Altfeld MA, Livingston B, Reshamwala N, Nguyen PT, Addo MM, Shea A, Newman M, Fikes J, Sidney J, Wentworth P, Chesnut R, Eldridge RL, Rosenberg ES, Robbins GK, Brander C, Sax PE, Boswell S, Flynn T, Buchbinder S, Goulder PJ, Walker BD, Sette A, Kalams SA. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J Virol. 2001 Feb; 75(3):1301-11.
    View in: PubMed
  161. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, Addo MM, Poon SH, Phillips MN, Robbins GK, Sax PE, Boswell S, Kahn JO, Brander C, Goulder PJ, Levy JA, Mullins JI, Walker BD. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med. 2001 Jan 15; 193(2):169-80.
    View in: PubMed
  162. Sax P. Visits to physicians: a critical review of the literature on ambulatory utilization in Israel. Isr Med Assoc J. 2001 Jan; 3(1):53-8.
    View in: PubMed
  163. Colson AE, Sax PE, Keller MJ, Turk BK, Pettus PT, Platt R, Choo PW. Paronychia in association with indinavir treatment. Clin Infect Dis. 2001 Jan; 32(1):140-3.
    View in: PubMed
  164. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PW, D'Agostino RB, Grinspoon S. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001 Jan; 32(1):130-9.
    View in: PubMed
  165. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA. 2000 Jul 26; 284(4):472-7.
    View in: PubMed
  166. Mylonakis E, Paliou M, Sax PE, Skolnik PR, Baron MJ, Rich JD. Central nervous system aspergillosis in patients with human immunodeficiency virus infection. Report of 6 cases and review. Medicine (Baltimore). 2000 Jul; 79(4):269-80.
    View in: PubMed
  167. Colson AE, Sax PE. Sexual dysfunction and HIV infection. AIDS Clin Care. 2000 May; 12(5):39-41, 43, 45-6.
    View in: PubMed
  168. Cinti SK, Kaul DR, Sax PE, Crane LR, Kazanjian PH. Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents. Clin Infect Dis. 2000 Mar; 30(3):511-4.
    View in: PubMed
  169. Sax PE, Piliero PJ. Antiretroviral rounds. Personal and public consequences. AIDS Clin Care. 2000 Jan; 12(1):4-5.
    View in: PubMed
  170. Sax PE. More on stopping antiretroviral therapy. AIDS Clin Care. 1999 Dec; 11(12):100.
    View in: PubMed
  171. Sax PE. Viral load and perinatal transmission. AIDS Clin Care. 1999 Oct; 11(10):84.
    View in: PubMed
  172. Sax PE. Single-dose Nevirapine during pregnancy. AIDS Clin Care. 1999 Oct; 11(10):84-5.
    View in: PubMed
  173. Landovitz RJ, Sax PE. Symptomatic junctional bradycardia after treatment with nelfinavir. Clin Infect Dis. 1999 Aug; 29(2):449-50.
    View in: PubMed
  174. Joste NE, Sax PE, Pieciak WS. Cytologic detection of microsporidia spores in bile. A comparison of stains. Acta Cytol. 1999 Mar-Apr; 43(2):98-103.
    View in: PubMed
  175. Merrill DP, Martinez-Picado J, Tremblay C, Sax PE, Boswell SL, Wong JT, D'Aquila RT, Walker BD, Hirsch MS. Improved CD4 lymphocyte outgrowth in response to effective antiretroviral therapy. J Infect Dis. 1999 Feb; 179(2):345-51.
    View in: PubMed
  176. Brodie SB, Keller MJ, Ewenstein BM, Sax PE. Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS. 1998 Dec 24; 12(18):2433-7.
    View in: PubMed
  177. Deeks SG, Sax PE. Should we argue with success? AIDS Clin Care. 1998 Sep; 10(9):68, 72.
    View in: PubMed
  178. Dorman SE, Heller HM, Basgoz NO, Sax PE. Adjunctive corticosteroid therapy for patients whose treatment for disseminated Mycobacterium avium complex infection has failed. Clin Infect Dis. 1998 Mar; 26(3):682-6.
    View in: PubMed
  179. Keller MJ, Sax PE. Aspergillus sinusitis in two HIV-infected men. AIDS Clin Care. 1997 Dec; 9(12):94, 100.
    View in: PubMed
  180. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997 Nov 21; 278(5342):1447-50.
    View in: PubMed
  181. Sullivan D, Sax PE. AIDS deaths decline. AIDS Clin Care. 1997 Apr; 9(4):36, 33.
    View in: PubMed
  182. Brodie S, Sax P. Novel approaches to HIV antibody testing. AIDS Clin Care. 1997 Jan; 9(1):1-5, 10.
    View in: PubMed
  183. Elperin A, Sax P. A patient's guide to protease inhibitors. AIDS Clin Care. 1996 Oct; 8(10):83-4.
    View in: PubMed
  184. Sax P, Turk B. Advice to travelers living with HIV. AIDS Clin Care. 1996 Jul; 8(7):57-8.
    View in: PubMed
  185. Sax P, Flory J. Viral load testing. AIDS Clin Care. 1996 Apr; 8(4):31-2.
    View in: PubMed
  186. Sax P, Singer M. Routine immunization in HIV: helpful or harmful? AIDS Clin Care. 1996 Feb; 8(2):11-3, 15.
    View in: PubMed
  187. Kunches L, Sax P. Being in a research study. AIDS Clin Care. 1996 Jan; 8(1):5-6.
    View in: PubMed
  188. Sax PE, Boswell SL, White-Guthro M, Hirsch MS. Potential clinical implications of interlaboratory variability in CD4+ T-lymphocyte counts of patients infected with human immunodeficiency virus. Clin Infect Dis. 1995 Nov; 21(5):1121-5.
    View in: PubMed
  189. Sax P, Weinberger H. HIV and family living. Preventing the spread of HIV and other diseases. AIDS Clin Care. 1995 Oct; 7(10):83-4.
    View in: PubMed
  190. Sax PE, Rich JD, Pieciak WS, Trnka YM. Intestinal microsporidiosis occurring in a liver transplant recipient. Transplantation. 1995 Sep 27; 60(6):617-8.
    View in: PubMed
  191. McCormick P, Sax P. Blood tests and what they mean. AIDS Clin Care. 1995 Jul; 7(7):57-8.
    View in: PubMed
  192. Langlois W, Sax P. T-cell counts and what they mean. AIDS Clin Care. 1995 Apr; 7(4):31-2.
    View in: PubMed
  193. Rich JD, Sax PE, Kazanjian PH. Bacteremic H. influenzae type b infections and HIV. Am J Med. 1993 Jul; 95(1):118-9.
    View in: PubMed
  194. Sax P. Recent trends in drug utilization in Israel. Isr J Med Sci. 1992 Oct; 28(10):718-25.
    View in: PubMed
  195. Weinberg S, Spelton J, Sax P, Sofer G. Up to code: validating a chromatography system. Biotechnology (N Y). 1992 Aug; 10(8):870-2.
    View in: PubMed
  196. Tischler MD, Lee TH, McAndrew KA, Sax PE, Sutton MS, Lee RT. Clinical, echocardiographic and Doppler correlates of clinical instability with onset of atrial fibrillation. Am J Cardiol. 1990 Sep 15; 66(7):721-4.
    View in: PubMed
  197. Edelson JT, Tosteson AN, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA. 1990 Jul 4; 264(1):41-7.
    View in: PubMed
  198. Sax P. Availability and timing of new drugs in Israel: analysis and international comparison. J Clin Pharmacol. 1989 Nov; 29(11):967-74.
    View in: PubMed
  199. Sax P. Expenditure and consumption of medicines in Israel 1975-85: analysis of trends and elements of growth. Isr J Med Sci. 1988 Jun; 24(6):307-16.
    View in: PubMed
  200. Donbrow M, Sax P. Thermodynamic parameters of molecular complexes in aqueous solution: enthalpy-entropy compensation in a series of complexes of caffeine with beta- naphthoxyacetic acid and drug-related aromatic compounds. J Pharm Pharmacol. 1982 Apr; 34(4):215-24.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Sax's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_